Ideas & Happenings
Ideas & Happenings
Condor Software Raises $24 Million Series A Funding to Build the First Financial Intelligence Platform for Life Sciences
Condor Software, the Financial Intelligence Platform for life sciences, today announced it has closed a $24 million Series A funding round led by global software investor Insight Partners, with participation from Felicis, 645 Ventures, Pamir Ventures, SNR Ventures, Prebys Ventures, and Bramalea Partners. Condor has raised a total of $36 million in funding.
Pamir Ventures Portfolio Company Revalia Bio Awarded Up to $26.7M ARPA-H Contract
We at Pamir are pleased to share that our portfolio company Revalia Bio has been awarded a contract of up to $26.7M ARPA-H Contract.
Revalia Bio will serve as the technical lead on the project, which aims to develop advanced AI-driven models trained on human biological data to improve how drug safety and efficacy are predicted before clinical trials.
Pamir’s Dr Milad Aluozai published in ICLG
“The coming decade will reveal a stark divide between nations that viewed biotechnology as a collection of scientific breakthroughs and those that recognised it as a unified, sovereign industrial system. To secure the stack is no longer merely an act of optimisation; it is a prerequisite for sovereignty in the century of biology.”
We are proud to share that our Partner, Dr Milad Aluozai, in collaboration with peers at Norton Rose Fulbright, has published a new article in the ICLG Digital Health Laws and Regulations 2026 report titled “The Geopolitical Tipping Point: Forecasting Global Bio-Industrial Technology Stack (BITS) Dominance Through 2050.”
Founders Summit 2026
Pamir co-hosted the Founders Summit in Palm Beach, FL with a group of high-level executives, industry leaders, and founders. Speakers included Ken Langone (Co-founder of Home Depot), Bob Langer (Co-Founder of Moderna), Michelle McGann (Professional golfer), and others.
Dr. Shambhawi
Chief Scientist, GreenCat
Scientist to founder
A series of conversations understanding the journey from theoretical science to practical industry functionality.
Shambhawi co-founded GreenCat, a Pamir portfolio company focused on revolutionizing catlaysis discovery across industries. Shambhawi's work started as a series of equations. Today GreenCat is engaging with some of the largest giants in the chemicals, petrochemicals, an pharma spaces.
JPM Breakfast 2026
At JPM 2026, Pamir partners Milad Alucozai and Anand Subramanian hosted a private breakfast in conjunction with Norton Rose Fulbright, convening leading healthcare founders and investors. The discussion focused on clinical proof over hype, the rise of biology native AI platforms and the growing demand for measurable outcomes and financial discipline across biotech and digital health.
Condor Software Raises $24 Million Series A Funding to Build the First Financial Intelligence Platform for Life Sciences
Condor Software, the Financial Intelligence Platform for life sciences, today announced it has closed a $24 million Series A funding round led by global software investor Insight Partners, with participation from Felicis, 645 Ventures, Pamir Ventures, SNR Ventures, Prebys Ventures, and Bramalea Partners. Condor has raised a total of $36 million in funding.
Pamir Ventures Portfolio Company Revalia Bio Awarded Up to $26.7M ARPA-H Contract
We at Pamir are pleased to share that our portfolio company Revalia Bio has been awarded a contract of up to $26.7M ARPA-H Contract.
Revalia Bio will serve as the technical lead on the project, which aims to develop advanced AI-driven models trained on human biological data to improve how drug safety and efficacy are predicted before clinical trials.
Pamir’s Dr Milad Aluozai published in ICLG
“The coming decade will reveal a stark divide between nations that viewed biotechnology as a collection of scientific breakthroughs and those that recognised it as a unified, sovereign industrial system. To secure the stack is no longer merely an act of optimisation; it is a prerequisite for sovereignty in the century of biology.”
We are proud to share that our Partner, Dr Milad Aluozai, in collaboration with peers at Norton Rose Fulbright, has published a new article in the ICLG Digital Health Laws and Regulations 2026 report titled “The Geopolitical Tipping Point: Forecasting Global Bio-Industrial Technology Stack (BITS) Dominance Through 2050.”
Founders Summit 2026
Pamir co-hosted the Founders Summit in Palm Beach, FL with a group of high-level executives, industry leaders, and founders. Speakers included Ken Langone (Co-founder of Home Depot), Bob Langer (Co-Founder of Moderna), Michelle McGann (Professional golfer), and others.
Dr. Shambhawi
Chief Scientist, GreenCat
Scientist to founder
A series of conversations understanding the journey from theoretical science to practical industry functionality.
Shambhawi co-founded GreenCat, a Pamir portfolio company focused on revolutionizing catlaysis discovery across industries. Shambhawi's work started as a series of equations. Today GreenCat is engaging with some of the largest giants in the chemicals, petrochemicals, an pharma spaces.
JPM Breakfast 2026
At JPM 2026, Pamir partners Milad Alucozai and Anand Subramanian hosted a private breakfast in conjunction with Norton Rose Fulbright, convening leading healthcare founders and investors. The discussion focused on clinical proof over hype, the rise of biology native AI platforms and the growing demand for measurable outcomes and financial discipline across biotech and digital health.
Condor Software Raises $24 Million Series A Funding to Build the First Financial Intelligence Platform for Life Sciences
Condor Software, the Financial Intelligence Platform for life sciences, today announced it has closed a $24 million Series A funding round led by global software investor Insight Partners, with participation from Felicis, 645 Ventures, Pamir Ventures, SNR Ventures, Prebys Ventures, and Bramalea Partners. Condor has raised a total of $36 million in funding.
Pamir Ventures Portfolio Company Revalia Bio Awarded Up to $26.7M ARPA-H Contract
We at Pamir are pleased to share that our portfolio company Revalia Bio has been awarded a contract of up to $26.7M ARPA-H Contract.
Revalia Bio will serve as the technical lead on the project, which aims to develop advanced AI-driven models trained on human biological data to improve how drug safety and efficacy are predicted before clinical trials.
Pamir’s Dr Milad Aluozai published in ICLG
“The coming decade will reveal a stark divide between nations that viewed biotechnology as a collection of scientific breakthroughs and those that recognised it as a unified, sovereign industrial system. To secure the stack is no longer merely an act of optimisation; it is a prerequisite for sovereignty in the century of biology.”
We are proud to share that our Partner, Dr Milad Aluozai, in collaboration with peers at Norton Rose Fulbright, has published a new article in the ICLG Digital Health Laws and Regulations 2026 report titled “The Geopolitical Tipping Point: Forecasting Global Bio-Industrial Technology Stack (BITS) Dominance Through 2050.”
Founders Summit 2026
Pamir co-hosted the Founders Summit in Palm Beach, FL with a group of high-level executives, industry leaders, and founders. Speakers included Ken Langone (Co-founder of Home Depot), Bob Langer (Co-Founder of Moderna), Michelle McGann (Professional golfer), and others.
Dr. Shambhawi
Chief Scientist, GreenCat
Scientist to founder
A series of conversations understanding the journey from theoretical science to practical industry functionality.
Shambhawi co-founded GreenCat, a Pamir portfolio company focused on revolutionizing catlaysis discovery across industries. Shambhawi's work started as a series of equations. Today GreenCat is engaging with some of the largest giants in the chemicals, petrochemicals, an pharma spaces.
JPM Breakfast 2026
At JPM 2026, Pamir partners Milad Alucozai and Anand Subramanian hosted a private breakfast in conjunction with Norton Rose Fulbright, convening leading healthcare founders and investors. The discussion focused on clinical proof over hype, the rise of biology native AI platforms and the growing demand for measurable outcomes and financial discipline across biotech and digital health.